Pulmonary micropapillary‐type adenosquamous carcinoma sharing epidermal growth factor receptor mutation in adenocarcinoma and squamous cell carcinoma

Abstract

Adenosquamous lung carcinoma (AdSqLC) has a worse prognosis than adenocarcinoma (ADC) or squamous cell carcinoma (SQCC). Micropapillary pattern in lung ADC is an additional poor prognostic factor. We describe a rare case of AdSqLC with epidermal growth factor receptor (EGFR) mutation in both the micropapillary‐ADC and SQCC components, showing long‐term response to gefitinib. A 60‐year‐old woman underwent right lower lobectomy for primary lung cancer. Histopathological examination demonstrated adenosquamous carcinoma comprising micropapillary‐ADC and moderately differentiated SQCC. EGFR exon 19 deletions mutation was detected in both the ADC and SQCC components. Gefitinib was administered for multiple metastatic recurrences on bilateral lung, resulting in remarkable shrinkage of visible lesions. The efficacy of gefitinib lasted for 31 months after the induction. AdSqLCs harbouring the EGFR mutation in both the ADC and SQCC components may well benefit from EGFR tyrosine kinase inhibitors, especially when they contain micropapillary‐ADC component that correlates with frequent EGFR mutations.

Mucinous tubular and spindle cell carcinoma with a high nuclear grade and micropapillary pattern: A case report

“…A micropapillary growth pattern in carcinoma was first reported for breast cancer ( 6 ). Currently, micropapillary growth pattern is well known in various carcinomas, such as lung adenocarcinoma ( 7 ), colorectal adenocarcinoma ( 8 ), gastric adenocarcinoma ( 9 ), and urothelial carcinoma ( 10 ). However, micropapillary growth pattern in renal cell carcinoma (RCC) is extremely rare ( 11 ).…”

Mutation Analysis of EGFR Gene in Patients with Non-Small Cell Lung Cancer in Xinjiang

“…A large proportion of patients die from the recurrence of lung cancer [10] [11]. With the rapid development of targeted therapy, more and more studies have begun to explore the application of EGFR-TKIs in the adjuvant therapy of early NSCLC after operation [12] [13] [14]. Research proved that EGFR patients with mutations who received EGFR-TKIs targeted therapy after radical surgery for lung cancer and after completing adjuvant chemotherapy were less able to reduce the risk of postoperative recurrence than those who were not accepted EGFR-TKIs; there is also a trend to extend the overall survival (OS) (41.6 months vs 32.…”